MetLife Investment Management LLC Sells 13,047 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

MetLife Investment Management LLC cut its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 17.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 62,990 shares of the company’s stock after selling 13,047 shares during the quarter. MetLife Investment Management LLC’s holdings in Taysha Gene Therapies were worth $109,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock valued at $6,182,000 after acquiring an additional 9,591 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after purchasing an additional 11,390 shares during the period. Privium Fund Management B.V. increased its position in shares of Taysha Gene Therapies by 12.4% during the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company’s stock worth $233,000 after buying an additional 14,900 shares during the period. Cibc World Markets Corp bought a new position in Taysha Gene Therapies during the fourth quarter worth $28,000. Finally, E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the fourth quarter valued at $31,000. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Up 1.4 %

NASDAQ TSHA opened at $2.13 on Friday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $4.32. The business has a 50 day moving average price of $1.65 and a 200-day moving average price of $1.81. The company has a market cap of $436.77 million, a price-to-earnings ratio of 3.38 and a beta of 0.90.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. As a group, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.